Cargando…

Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse

Pediatric drug development is a challenging process due to the rarity of the population, the need to meet regulatory requirements across the globe, the associated uncertainty in extrapolating data from adults, the paucity of validated biomarkers, and the lack of systematic testing of drugs in pediat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shebley, Mohamad, Menon, Rajeev M., Gibbs, John P., Dave, Nimita, Kim, Su Y., Marroum, Patrick J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590144/ https://www.ncbi.nlm.nih.gov/pubmed/30562405 http://dx.doi.org/10.1002/jcph.1359

Ejemplares similares

Chihuahua; storehouse of storms
por: Lister, Florence Cline
Publicado: (1966)

A storehouse for splicing proteins?
por: Leslie, Mitch
Publicado: (2014)

What a Storehouse Is the Voluntary Hospital!
Publicado: (1914)

Are there ancient editions of Paul's letters?: The Euthalian apparatus as a storehouse of tradition
por: Allen, Garrick V.
Publicado: (2023)

Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure
por: Mukherjee, Dwaipayan, et al.
Publicado: (2022)

Mechanistic Modeling of Intra‐Tumor Spatial Distribution of Antibody‐Drug Conjugates: Insights into Dosing Strategies in Oncology
por: Weddell, Jared, et al.
Publicado: (2020)

Bedside to Bench: Integrating Quantitative Clinical Pharmacology and Reverse Translation to Optimize Drug Development
por: Gibbs, John P., et al.
Publicado: (2017)

Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
por: Chiney, Manoj S., et al.
Publicado: (2019)

Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
por: Mukherjee, Dwaipayan, et al.
Publicado: (2018)

Traditional uses, phytochemistry, pharmacology and toxicology of garlic (Allium sativum), a storehouse of diverse phytochemicals: A review of research from the last decade focusing on health and nutritional implications
por: Tudu, Champa Keeya, et al.
Publicado: (2022)

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
por: Shebley, Mohamad, et al.
Publicado: (2019)

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
por: Liu, Stephanie N., et al.
Publicado: (2021)

Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?
por: Shebley, Mohamad
Publicado: (2018)

Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids
por: Beck, Denise, et al.
Publicado: (2022)

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?
por: Templeton, IE, et al.
Publicado: (2016)

Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics
por: Perwitasari, D. A., et al.
Publicado: (2011)

Pharmacogenomics, Theranostics and Personalized Medicine - the complexities of clinical trials: challenges in the developing world()
por: Limaye, Nimita
Publicado: (2013)

Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations
por: Barry, Elly, et al.
Publicado: (2021)

Drug repositioning can accelerate discovery of pharmacological chaperones
por: Hay Mele, Bruno, et al.
Publicado: (2015)

Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development
por: Helmlinger, Gabriel, et al.
Publicado: (2019)

Integrating real‐world data to accelerate and guide drug development: A clinical pharmacology perspective
por: Zhao, Xiaochen, et al.
Publicado: (2022)

Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet
por: Badawi, Mohamed, et al.
Publicado: (2022)

An institutional audit of the use of novel drugs in pediatric oncology
por: Lee, Justin, et al.
Publicado: (2021)

Innovation in Oncology Drug Development
por: Huber, Matthew, et al.
Publicado: (2019)

A Personalized Medicine Approach Using Clinical Utility Index and Exposure‐Response Modeling Informed by Patient Preferences Data
por: Winzenborg, Insa, et al.
Publicado: (2020)

Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm
por: Chelliah, Vijayalakshmi, et al.
Publicado: (2020)

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis
por: Stodtmann, Sven, et al.
Publicado: (2021)

Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and Dasabuvir
por: Shebley, M, et al.
Publicado: (2017)

Pediatric Oncology
por: Morris-Jones, P. H.
Publicado: (1981)

Pediatric Oncology
Publicado: (2001)

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology
por: Peskov, Kirill, et al.
Publicado: (2019)

Response to “Quantitative Prediction of Drug‐Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is It Worth?”
por: Templeton, IE, et al.
Publicado: (2017)

Phantom Limb Pain in Pediatric Oncology
por: DeMoss, Patrick, et al.
Publicado: (2018)

Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis
por: Dave, Nimita, et al.
Publicado: (2019)

Drug-Diagnostics Co-Development in Oncology
por: Jørgensen, Jan Trøst
Publicado: (2014)

Drug-Diagnostics Co-Development in Oncology
por: Simon, Richard
Publicado: (2013)

PHC: the future of oncology drug development
por: Yao, Yihong
Publicado: (2012)

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
por: Metzger, Ingrid F., et al.
Publicado: (2019)

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women
por: Nader, Ahmed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cl6f42cqs4nmivgu1tdqkonn73